[artículo] 
inThe Journal of Clinical Psychiatry > Año 2018 - Vol. 79 - No.4 (Julio - Agosto) . - pp. 11-17

Título :	A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder
Tipo de documento:	texto impreso
Autores:	Mary Hobart, Autor ; Aleksandar Skuban, Autor ; Peter Zhang, Autor
Fecha de publicación:	2018
Artículo en la página:	pp. 11-17
Idioma :	Inglés (eng)
Palabras clave:	Brexpiprazole, Placebo, Trastorno depresivo mayor, Antidepresivos.
Resumen:	To assess the efficacy, safety, and tolerability of brexpiprazole as adjunct to antidepressant treatment (ADT) in adults with major depressive disorder (MDD) and inadequate response to ADTs.
Link:	./index.php?lvl=notice_display&id=13459

[artículo] A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder [texto impreso] / Mary Hobart, Autor ; Aleksandar Skuban, Autor ; Peter Zhang, Autor . - 2018 . - pp. 11-17.
Idioma : Inglés (eng)
in The Journal of Clinical Psychiatry > Año 2018 - Vol. 79 - No.4 (Julio - Agosto) . - pp. 11-17

Palabras clave:	Brexpiprazole, Placebo, Trastorno depresivo mayor, Antidepresivos.
Resumen:	To assess the efficacy, safety, and tolerability of brexpiprazole as adjunct to antidepressant treatment (ADT) in adults with major depressive disorder (MDD) and inadequate response to ADTs.
Link:	./index.php?lvl=notice_display&id=13459